Award

Ensuring a Successful Transition from Pap to HPV DNA Testing in Primary Cervical Cancer Screening: Exploring and Listening to Canadian Women's Needs is Critical for Effective Public Policy Change

Description: In their lifetime, 75% of sexually active women will be infected with the Human Papillomavirus (HPV) which is the proven cause of cervical cancer. In Canada, the Pap test (smear) is used to monitor changes in the cervix, usually every 2-3 years. Too many women do not participate regularly in screening (defined as underscreened), especially vulnerable groups (e.g., recent immigrants, low household income). A new cervical screening test detects the HPV virus in cervical cells (HPV test), offers greater protection than the Pap test against cervical cancer and permits extending the testing interval to 5 years or more. Provinces are planning to replace the Pap test with the HPV test, but public health authorities are concerned that women are not yet prepared. In 2017, Australia postponed replacing the Pap test with the HPV test because women did not know that HPV causes cervical cancer, were worried that a cancer could be missed due to longer testing intervals and believed that the government only wanted to save money by extending the screening interval. In Canada, we know little about women's information needs and their perceived barriers (fears and worries) regarding the HPV test. As a result, they might hesitate or refuse the HPV test and miss the opportunity of early detection and prevention of cervical cancer. In this study, we will carry out an internet-based survey of women age 21 to 70 across Canada and ask about their knowledge, attitudes and beliefs, and their willingness and intentions to accept the HPV test. We will use scientifically valid questions to understand perceived benefits and barriers to the HPV test. Our international research team has many years of experience in studying HPV vaccination and HPV testing decision-making. This study is critical for informing public health authorities about how to educate and encourage women to participate in HPV testing in the most sensitive and timely manner with the goal of improving cervical cancer prevention.
Amount: CA$265,600
Funding type: research
Funder scheme: Project Grant
Start date: 2019-10-01
End date: 2021-09-30
Investigator: Zeev Rosberger (lead)
Institutions: Lady Davis Institute for Medical Research, Lady Davis Institute for Medical Research (Mtl)
Subfield: Epidemiology
Field: Medicine
Funded outputs count: 0
Funder award ID: 165905_1
OpenAlex ID: G4056727462